OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
bcmaxcd3 bispecific antibody,relapsed/refractory multiple myeloma,multiple myeloma,cytokine release syndrome
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要